BMY vs THAR · P/E 17, rev $24.46B vs $187.4M cap
Bristol-Myers Squibb Company (BMY) versus Tharimmune Inc. (THAR) — a side-by-side from cached financials, not a winner call.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Chris Boerner.
Tharimmune Inc. (THAR) is a biotechnology company listed on NASDAQ.
Latest reported BMY revenue for 2026-06-30 was $24.46B. Net income was $5.99B. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
THAR does not have a complete income-statement cache yet.
BMY currently screens at market cap $95.36B and trailing P/E 17.5. THAR currently screens at market cap $187.4M.
Not investment advice. Open the BMY and THAR stock pages for the full models.
Not investment advice.